Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rhenium (186Re) obisbemeda - Plus Therapeutics

Next Previous
X
Search
Drug Profile

Rhenium (186Re) obisbemeda - Plus Therapeutics

Alternative Names: 186-Rheneium nanoliposome-Plus Therapeutics; 186RNL; Re-186; Rhenium-186 NanoLiposome; RNL™

Latest Information Update: 09 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plus Therapeutics
  • Class Antineoplastics; Heavy metals; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Meningeal carcinomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma
  • Phase I/II Meningeal carcinomatosis
  • Preclinical Brain cancer; Peritoneal cancer; Squamous cell cancer

Most Recent Events

  • 01 Oct 2024 Efficacy and adverse event data from the phase I/II ReSPECT-GBM trial released by Plus Therapeutics
  • 22 Aug 2024 Plus Therapeutics submits a new clinical protocol to US FDA for Meningeal carcinomatosis
  • 12 Aug 2024 Efficacy and adverse events data from a phase I/IIa ReSPECT-LM trial in Meningeal carcinomatosis released by Plus Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top